Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice.
We have investigated the effect of naringenin (NGEN) on tumor growth in various human cancer cell lines and sarcoma S-180-implanted mice. NGEN showed cytotoxicity in cell lines derived from cancer of the breast (MCF-7, MDA-MB-231), stomach (KATOIII, MKN-7), liver (HepG2, Hep3B, Huh7), cervix (Hela, Hela-TG), pancreas (PK-1), and colon (Caco-2) as well as leukemia (HL-60, NALM-6, Jurkat, U937). NGEN-induced cytotoxicity was low in Caco-2 and high in leukemia cells compared to other cell lines. NGEN dose-dependently induced apoptosis, with hypodiploid cells detected in both Caco-2 and HL-60 by flow cytometric analysis. In vivo, NGEN inhibited tumor growth in sarcoma S-180-implanted mice, following intraperitoneal or peroral injection once a day for 5 d. Naringin (NG) also inhibited tumor growth by peroral injection but not intraperitoneal injection. NGEN, one of the most abundant flavonoids in citrus fruits, may have a potentially useful inhibitory effect on tumor growth.
Kanno
Syu-Ichi
S
Department of Pharmacology and Toxicology, Cancer Research Institute, Tohoku Pharmaceutical University, Komatsushima, Sendai, Japan. syu-kan@tohoku-pahrm.ac.jp
Tomizawa
Ayako
A
Hiura
Takako
T
Osanai
Yuu
Y
Shouji
Ai
A
Ujibe
Mayuko
M
Ohtake
Takaharu
T
Kimura
Katsuhiko
K
Ishikawa
Masaaki
M
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D044950:Flavanones / Q000627:therapeutic use*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D008297:Male; D051379:Mice; D012510:Sarcoma 180 / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D044950:Flavanones; D006131:Growth Inhibitors; C005273:naringenin